SynthesisOncotarget2017
KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- p53 expression in patients with ulcerative colitis - associated with dysplasia and carcinoma: a systematic meta-analysis.BMC gastroenterology · 2017Pooled it
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- A novel LncRNA signature associated with cuproptosis for prognostic prediction and immune response assessment in rectum adenocarcinoma.Discover oncology · 2026Article
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version).Journal of the anus, rectum and colon · 2026Review
- Coexistence of P53 and KRAS mutations enhances ERK1/2 signaling by inducing EGR1 expression through mutp53 and c-JUN interaction.Oncogene · 2025Article
- The Role of Biomarkers in Surveillance of Ulcerative Colitis-Associated Colorectal Cancer: A Scoping Review.Journal of clinical medicine · 2025Review
- Network pharmacology and experimental validation of Compound Kushen Powder for the treatment of diarrhea in vivo.Veterinary and animal science · 2025Article
- Review
- A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel disease.Journal of Crohn's & colitis · 2025Article
- Emerging role of small RNAs in inflammatory bowel disease and associated colorectal cancer (Review).International journal of molecular medicine · 2025Review
- Review
- Genetic Analysis of Biopsy Tissues from Colorectal Tumors in Patients with Ulcerative Colitis.Cancers · 2024Article
- Article
- Potential carcinogenic role of Reg IV in ulcerative colitis-associated colorectal neoplasia.Ecancermedicalscience · 2024Article
- Meta‑analysis of the autophagy‑associated protein LC3 as a prognostic marker in colorectal cancer.Experimental and therapeutic medicine · 2023Article
- Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management.Cancers · 2023Review
- Alterations in p53, Microsatellite Stability and Lack of MUC5AC Expression as Molecular Features of Colorectal Carcinoma Associated with Inflammatory Bowel Disease.International journal of molecular sciences · 2023Article
- Prognostic value of primary tumor sidedness in patients with non-metastatic IBD related CRC - Is it the exception to the rule?Surgical oncology · 2022Article
- Expression of the methylcytosine dioxygenase ten-eleven translocation-2 and connexin 43 in inflammatory bowel disease and colorectal cancer.World journal of gastroenterology · 2022Article
- Targeted Sequencing of Cytokine-Induced PI3K-Related Genes in Ulcerative Colitis, Colorectal Cancer and Colitis-Associated Cancer.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although KRAS and TP53 mutations are common in both inflammatory bowel disease-associated colorectal cancer (IBD-CRC) and sporadic colorectal cancer (S-CRC), molecular events leading to carcinogenesis may be different. Previous studies comparing the frequency of KRAS and TP53 mutations in IBD-CRC and S-CRC were inconsistent. We performed a meta-analysis to compare the presence of KRAS and TP53 mutations among patients with IBD-CRC, S-CRC, and IBD without dysplasia. A total of 19 publications (482 patients with IBD-CRC, 4,222 with S-CRC, 281 with IBD without dysplasia) met the study inclusion criteria. KRAS mutation was less frequent (RR=0.71, 95%CI 0.56-0.90; P=0.004) while TP53 mutation was more common (RR=1.24, 95%CI 1.10-1.39; P<0.001) in patients with IBD-CRC compared to S-CRC. Both KRAS (RR=3.09, 95%CI 1.47-6.51; P=0.003) and TP53 (RR=2.15, 95%CI 1.07-4.31 P=0.03) mutations were more prevalent in patients with IBD-CRC compared to IBD without dysplasia. In conclusion, IBD-CRC and S-CRC appear to have biologically different molecular pathways. TP53 appears to be more important than KRAS in IBD-CRC compared to S-CRC. Our findings suggest possible roles of TP53 and KRAS as biomarkers for cancer and dysplasia screening among patients with IBD and may also provide targeted therapy in patients with IBD-CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.